Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Helius Medical Technologies reports Q1 revenue, eyes CMS reimbursement boost

Helius Medical Technologies navigated Q1 2024 with a focus on reimbursement, FDA approval, and financial sustainability, supported by financing and market expansion initiatives.
Progress in securing reimbursement, expanding market reach, and addressing demand signals growth potential and market acceptance for the company's products.
Challenges in achieving profitability and executing development plans underscore the importance of timely reimbursement and effective operational strategies.

Helius Medical Technologies navigates revenue challenges with strategic growth initiatives

Helius Medical Technologies faces challenges from program terminations impacting revenue and ongoing operating losses, but maintains a strong cash position with no debt.
Efforts to expand access to PoNS Therapy through strategic partnerships and sales initiatives present growth opportunities in the MS and stroke treatment markets.
The company's financial performance in Q2 2024 reflects a mixed picture of revenue decline, operational losses, and cash stability, with potential for growth pending reimbursement determinations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

NEWTOWN, Pa., Oct.  24, 2019  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update outlining the Company’s US regulatory strategy following its pre-submission meeting with the U.S. Food and Drug Administration (“FDA”).

Helius Medical Technologies, Inc. Announces Update on US Regulatory Strategy Following Pre-Submission Meeting with FDA

Demand for traumatic brain injury management brings revolutionary neurological health technologies to Canada’s capital Demand for traumatic brain injury management brings revolutionary neurological health technologies to Canada’s capital

Helius Medical Technologies, Inc. and HealthTech Connex Announce Grand Opening of Canada’s Fifth PoNS Treatment™ Clinic

NEWTOWN, Pa., Sept.  13, 2019  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that Clinique Cortex has been authorized to provide PoNS Treatment™ in Quebec City Canada, giving Canadians living in Quebec City local access to the PoNS Treatment™.  Clinique Cortex joins the current roster of existing clinics authorized to provide the PoNS Treatment, including Neurotherapy Montreal, Surrey Neuroplasticity Clinic, Advantage 4 Athletes Training Centre and Therapy Clinic in Markham, Ontario; Synaptic Spinal Cord Injury and Neuro Rehabilitation Centre in Calgary, Alberta; and Apollo South Physical Therapy Centre in Ottawa, Ontario.

Helius Medical Technologies, Inc. Announces Addition of a New PoNS™ Clinic in Quebec City, Canada

NEWTOWN, Pa., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update from early Canadian clinical experience with PoNS.

Helius Medical Technologies, Inc. Provides a Business Update on Clinical Experience to Date in Canada

Helius Medical Technologies' (HSDT) CEO Phil Deschamps on Q2 2019 Results - Earnings Call Transcript

Helius Medical Technologies, Inc. (HSDT) CEO Phil Deschamps on Q1 2019 Results - Earnings Call Transcript

Helius Medical Technologies Inc. shares slid 56% premarket Wednesday, after the company said the U.S. Food and Drug Administration has declined its request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device (PoNS).

Helius Medical says FDA has refused request for approval of device used in brain injuries

News for Helius Medical Technologies Stock (HSDT)